UK Life Sciences Super Cluster announced as support for life sciences is bolstered

27 January 2010

The UK government yesterday afternoon announced plans for a new UK Life Sciences Super Cluster, supported by £1 million ($1.6 million) of government investment. Bringing together industry, academia and the National Health Service, it will help deliver the next generation of medicines and technologies needed to support people suffering from chronic diseases, it maintains.

At its heart will be the creation of Therapeutic Capability Clusters. These will be one-stop-shops for the UK's top research in specific fields. They will bring together academic and NHS centers of excellence, which will work with industry to harness the UK's expert capabilities and work on early stage clinical development and experimental medicine.

The new Life Sciences Super Cluster will be kick-started later this year with a pilot in immunology and inflammation focussing on disease areas such as asthma and rheumatoid arthritis, according to a statement from the Department for Business, Innovation and Skills.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >